Attached files
file | filename |
---|---|
8-K - SKYSTAR BIO-PHARMACEUTICAL CO | v205591_8k.htm |
EX-16.1 - SKYSTAR BIO-PHARMACEUTICAL CO | v205591_ex16-1.htm |
NEWS
RELEASE
Skystar
Bio-Pharmaceutical Appoints Crowe Horwath LLP as New Independent
Auditor
XI’AN, CHINA – December 15, 2010 -- -
Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ("Skystar" or the "Company"),
a China-based manufacturer
and distributor of veterinary medicines, vaccines, micro-organisms and feed
additives, today announced that its Audit Committee and Board of Directors
appointed Crowe Horwath LLP as the Company’s new independent auditor, to replace
Frazer Frost, LLP, effective immediately.
Mr.
Weibing Lu, CEO commented, “We would like to thank Frazer Frost, LLP for its
service to Skystar. We are pleased to have selected Crowe Horwath, LLP, who is
ranked amongst the top ten largest global public accounting firms and in the
United States. Skystar believes that the change in independent
auditing firm will further strength Skystar’s corporate governance and
transparency policies.”
To be
added to the Company's email distribution for future news releases, please send
your request to skystar@grayling.com.
About
Crowe Horwath
Crowe
Horwath LLP (www.crowehorwath.com) is one of the largest public accounting and
consulting firms in the United States. Under its core purpose of “Building Value
with Values®,” Crowe assists public and private company clients in reaching
their goals through audit, tax, advisory, risk and performance services. With 26
offices and 2,400 personnel, Crowe is recognized by many organizations as one of
the country's best places to work. Crowe serves clients worldwide as an
independent member of Crowe Horwath International, one of the largest networks
in the world, consisting of more than 140 independent accounting and management
consulting firms with offices in more than 400 cities around the
world.
About
Skystar Bio-Pharmaceutical Company
Skystar
is a China-based developer and distributor of veterinary healthcare and medical
care products. Skystar has four product lines (veterinary medicines,
micro-organisms, vaccines and feed additives) and over 170 products. Skystar has
formed strategic sales distribution networks covering 29 provinces throughout
China. For additional information, please visit
http://www.skystarbio-pharmaceutical.com.
Contacts:
Skystar Bio-Pharmaceutical Company
Scott
Cramer, Director –Corporate Development and U.S. Representative
(407)
645-4433
Page 1 of
2
Grayling
Investor
Relations
Christopher
Chu
(646)
284-9426
christopher.chu@grayling.com
Page 2
of 2